Table. Characteristics of Patients With SARS-CoV-2–Positive and SARS-CoV-2–Negative Tests, by Age Group.
| Characteristic | Patients, No. (%) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| <18 y | 18-49 y | 50-64 y | 65-74 y | ≥75 y | Totala | |||||||
| Positive | Negative | Positive | Negative | Positive | Negative | Positive | Negative | Positive | Negative | Positive | Negative | |
| Patients tested for SARS-CoV-2 | 454 (3.9) | 11 255 (96.1) | 10 619 (7.1) | 138 311 (92.9) | 11 602 (9.7) | 108 071 (90.3) | 9642 (9.1) | 95 774 (90.9) | 10 287 (8.7) | 107 394 (91.3) | 42 604 (8.5) | 460 805 (91.5) |
| Malea | 210 (46.3) | 5788 (51.4) | 4973 (46.8) | 48 204 (34.9) | 6487 (55.9) | 59 534 (55.1) | 5112 (53.0) | 49 148 (51.3) | 4810 (46.8) | 46 412 (43.2) | 21 592 (50.7) | 209 086 (45.4) |
| Female | 244 (54.7) | 5467 (48.6) | 5646 (53.2) | 90 107 (65.1) | 5115 (44.1) | 48 537 (44.9) | 4530 (47.0) | 46 626 (48.7) | 5477 (53.2) | 60 982 (56.8) | 21 012 (49.3) | 251 719 (54.6) |
| ≥1 underlying severe illness or conditiona,b | 145 (31.9) | 2610 (23.2) | 6905 (65.0) | 58 767 (42.5) | 9474 (81.7) | 73 221 (67.8) | 8113 (84.1) | 67 738 (70.7) | 8611 (83.7) | 75 060 (69.9) | 33 248 (78.0) | 277 396 (60.2) |
| In-hospital deatha | 1 (0.2) | 45 (0.4) | 274 (2.6) | 1051 (0.8) | 922 (7.9) | 2576 (2.4) | 1359 (14.1) | 3223 (3.4) | 2149 (20.9) | 4812 (4.5) | 4705 (11.0) | 11 707 (2.5) |
| LOS for total populationa | ||||||||||||
| Mean (SD), d | 4.5 (11.2) | 5.3 (14.9) | 6.1 (8.7) | 4.1 (6.5) | 8.8 (12.0) | 5.5 (8.0) | 9.7 (11.3) | 5.8 (7.6) | 9.7 (19.7) | 5.7 (9.0) | 8.5 (13.6) | 5.2 (8.0) |
| Median (range), d | 2 (1-150) | 2 (1-317) | 4 (1-165) | 2 (1-620) | 5 (1-619) | 3 (1-457) | 6 (1-278) | 4 (1-482) | 6 (1-462) | 4 (1-514) | 5 (1-619) | 3 (1-620) |
| ICU admissiona | ||||||||||||
| Patients admitted to ICU | 92 (20.3) | 1736 (15.5) | 1810 (17.0) | 12 938 (9.4) | 2766 (23.8) | 18 162 (16.8) | 2630 (24.5) | 16 893 (17.5) | 2288 (22.2) | 15 988 (14.9) | 9586 (22.5) | 65 717 (14.3) |
| Total LOSa | ||||||||||||
| Mean (SD), d | 4.7 (5.0) | 6.6 (14.3) | 13.3 (14.9) | 8.5 (11.0) | 16.2 (14.8) | 9.8 (11.2) | 16.0 (13.3) | 9.7 (10.6) | 12.7 (11.0) | 8.7 (8.3) | 14.7 (13.7) | 9.2 (10.5) |
| Median (range), d | 3 (1-26) | 3 (1-249) | 9 (1-165) | 5 (1-303) | 12 (1-152) | 6 (1-218) | 12 (1-102) | 7 (1-370) | 10 (1-132) | 6 (1-241) | 11 (1-165) | 6 (1-370) |
| ICU LOSa | ||||||||||||
| Mean (SD), d | 3.3 (4.1) | 3.4 (8.6) | 7.6 (10.5) | 3.7 (5.5) | 9.6 (10.9) | 4.2 (5.9) | 9.2 (10.0) | 4.0 (5.6) | 6.4 (6.8) | 3.4 (4.3) | 8.3 (9.8) | 3.8(5.5) |
| Median (range), d | 2 (1-26) | 2 (1-191) | 4 (1-110) | 2 (1-95) | 6 (1-117) | 2 (1-114) | 6 (1-86) | 2 (1-253) | 4 (1-61) | 2 (1-81) | 5 (1-117) | 2 (1-253) |
Abbreviations: ICU, intensive care unit; LOS, length of stay.
P < .001 for comparison of patients with SARS-CoV-2–positive tests vs those with SARS-CoV-2–negative tests.
Includes the following baseline conditions occurring within the first 3 days of hospital admissions as determined by the maximum value of surrogate laboratory results: renal insufficiency (serum creatinine [SCr] >2.0 mg/dL [to convert to micromoles per liter, multiply by 88.4]); kidney failure (blood urea nitrogen >100 and SCr >3.0 mg/dL); suspected sepsis (lactic acid >2.0 or >4.0 mmol/L); suspected heart failure (brain-type natriuretic peptide [BNP] >400 pg/mL [to convert to nanograms per liter, multiply by 1.0] or N-terminal pro BNP >900 pg/mL); myocardial inflammation (doubling of troponin drawn within 6 hours final value: troponin ≥0.4 ng/L [to convert to micrograms per liter, multiply by 1.0], troponin T ≥15 ng/L [to convert to micrograms per liter, multiply by 1.0] in male patients, troponin T ≥10 ng/L in female patients, troponin I >0.04 ng/mL [to convert to micrograms per liter, multiply by 1.0]); liver dysfunction (any of the following: alanine aminotransferase >60 U/L [to convert to microkatals per liter, multiply by 0.0167], aspartate aminotransferase >80 U/L [to convert to microkatals per liter, multiply by 0.0167], serum albumin <3.0 g/dL [to convert to grams per liter, multiply by 10], international normalized ratio >2.0 [and not currently receiving warfarin, rivaroxaban, apixaban, edoxaban, or betrixaban]); cytokine stimulation (any of the following: fibrinogen <250 mg/dL [to convert to grams per liter, multiply by 0.01], C-reactive protein >7.0 mg/dL [to convert to milligrams per liter, multiply by 10], D-dimer [dimerized plasmin fragment D] >1000 ng/mL [to convert to nanomoles per liter, multiply by 5.476], erythrocyte sedimentation rate >30 mm/h, or triglycerides >265 mg/dL [to convert to millimoles per liter, multiply by 0.0113]).